// App-Quantinova.ai

: The Von Willebrand Factor Tyr2561 Allele Is a Gain-of-Function Variant and a Potential Risk Factor for Early Myocardial Infarction

Researchers

Presenter

  • Reinhard Schneppenheim

Principal Investigators

  • Natalie Hellermann

  • Maria Alexandra Brehm

  • Ulrike Klemm

  • Tobias Obser

  • Volker Huck

  • Stefan W Schneider

  • Cecile V. Denis

  • Alexander Tischer

  • Matthew Auton

  • Winfried Maerz

  • Emma-Ruoqi Xu

  • Matthias Wilmanns

  • Rainer B. Zotz

Medical Centers

  • Department of Pediatric Hematology and Oncology, University Medical Center Eppendorf, Hamburg, Germany

  • Medicum, Detmold, Germany

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • Inserm, UMR-S 1176, Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN

  • Department of Oncology, Mayo Clinic, Rochester, MN

  • Mayo Clinic, Rochester, MN

  • University Clinic Heidelberg, Heidelberg, Germany

  • European Molecular Biology Laboratory (EMBL), Heidelberg, Germany

  • Department of Hemostasis and Transfusion Medicine, Heinrich Heine University Medical Center, Duesseldorf, DEU

Locations

  • Germany

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

Disease

  • Coronary Artery Disease

  • Myocardial infarction

  • Venous thrombosis

Biomarkers

  • von Willebrand factor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved